Liang Liang,Li Yingzi.Research progress on the protective mechanisms of anti-inflammatory active substances in neonatal necrotizing enterocolitis[J].Journal of Clinical Pediatric Surgery,2025,(07):697-700.[doi:10.3760/cma.j.cn101785-202405058-018]
抗炎活性物质对新生儿坏死性小肠结肠炎保护机制的研究进展
- Title:
- Research progress on the protective mechanisms of anti-inflammatory active substances in neonatal necrotizing enterocolitis
- Keywords:
- Enterocolitis; Necrotizing; Inflammation Mediators; Defense Mechanisms; Child
- 摘要:
- 新生儿坏死性小肠结肠炎(necrotizing enterocolitis,NEC)是导致新生儿死亡的主要疾病之一。NEC 的保护机制与维护肠上皮屏障功能、调节免疫反应、增加肠道血流灌注和促进粘蛋白分泌等抗炎机制有关。其中,胰岛素生长因子-1在动物模型和初步临床试验中证实其对NEC的预防作用;表皮生长因子则通过降低肠道通透性和抑制肠道细菌易位等机制维护肠道屏障功能;近年来有关褪黑素、肠道三叶因子对新生儿坏死性小肠结肠炎保护机制的研究也在陆续开展。本文就抗炎活性物质对NEC保护机制的研究进展进行综述,为其临床应用提供理论依据。
- Abstract:
- Neonatal necrotizing enterocolitis (NEC) is one of the leading causes of neonatal mortality.The protective mechanisms against NEC involve various anti-inflammatory processes,including the maintenance of intestinal epithelial barrier function,modulation of immune responses,enhancement of intestinal blood perfusion,and promotion of mucin secretion.Among them,insulin-like growth factor-1 has demonstrated preventive effects against NEC in animal models and preliminary clinical trials.Epidermal growth factor helps maintain barrier function by reducing intestinal permeability and suppressing bacterial translocation.In recent years,research has also been carried out on the protective mechanisms of anti-inflammatory active substances in NEC,aiming to provide theoretical support for their clinical application.
参考文献/References:
[1] Stanikova A,Jouza M,Bohosova J,et al.Role of the microbiome in pathophysiology of necrotising enterocolitis in preterm neonates[J].BMJ Paediatr Open,2023,7(1):e002172.DOI:10.1136/bmjpo-2023-002172.
[2] Clark JA,Lane RH,Maclennan NK,et al.Epidermal growth factor reduces intestinal apoptosis in an experimental model of necrotizing enterocolitis[J].Am J Physiol Gastrointest Liver Physiol,2005,288(4):G755-G762.DOI:10.1152/ajpgi.00172.2004.
[3] Dvorak B.Milk epidermal growth factor and gut protection[J].J Pediatr,2010,156(2 Suppl):S31-S35.DOI:10.1016/j.jpeds.2009.11.018.
[4] Good M,Sodhi CP,Egan CE,et al.Breast milk protects against the development of necrotizing enterocolitis through inhibition of Toll-like receptor 4 in the intestinal epithelium via activation of the epidermal growth factor receptor[J].Mucosal Immunol,2015,8(5):1166-1179.DOI:10.1038/mi.2015.30.
[5] Banan A,Zhang LJ,Farhadi A,et al.PKC-β1 isoform activation is required for EGF-induced NF-κB inactivation and IκBα stabilization and protection of F-actin assembly and barrier function in enterocyte monolayers[J].Am J Physiol Cell Physiol,2004,286(3):C723-C738.DOI:10.1152/ajpcell.00329.2003.
[6] Damiano S,Morano A,Ucci V,et al.Dual oxidase 2 generated reactive oxygen species selectively mediate the induction of mucins by epidermal growth factor in enterocytes[J].Int J Biochem Cell Biol,2015,60:8-18.DOI:10.1016/j.biocel.2014.12.014.
[7] Mannon P,Reinisch W.Interleukin 13 and its role in gut defence and inflammation[J].Gut,2012,61(12):1765-1773.DOI:10.1136/gutjnl-2012-303461.
[8] Knoop KA,Coughlin PE,Floyd AN,et al.Maternal activation of the EGFR prevents translocation of gut-residing pathogenic Escherichia coli in a model of late-onset neonatal sepsis[J].Proc Natl Acad Sci U S A,2020,117(14):7941-7949.DOI:10.1073/pnas.1912022117.
[9] Van Landeghem L,Santoro MA,Mah AT,et al.IGF1 stimulates crypt expansion via differential activation of 2 intestinal stem cell populations[J].FASEB J,2015,29(7):2828-2842.DOI:10.1096/fj.14-264010.
[10] Corpeleijn WE,Van Vliet I,De Gast-Bakker DAH,et al.Effect of enteral IGF-1 supplementation on feeding tolerance,growth,and gut permeability in enterally fed premature neonates[J].J Pediatr Gastroenterol Nutr,2008,46(2):184-190.DOI:10.1097/MPG.0b013e31815affec.
[11] Hellstrom A,Ley D,Hallberg B,et al.IGF-1 as a drug for preterm infants:a step-wise clinical development[J].Curr Pharm Des,2017,23(38):5964-5970.DOI:10.2174/1381612823666171002114545.
[12] Guven A,Uysal B,Gundogdu G,et al.Melatonin ameliorates necrotizing enterocolitis in a neonatal rat model[J].J Pediatr Surg,2011,46(11):2101-2107.DOI:10.1016/j.jpedsurg.2011.06.040.
[13] Xiong XY,Bao ZK,Mi YH,et al.Melatonin alleviates neonatal necrotizing enterocolitis by repressing the activation of the NLRP3 inflammasome[J].Gastroenterol Res Pract,2022,2022:6920577.DOI:10.1155/2022/6920577.
[14] Ma F,Hao H,Gao XY,et al.Melatonin ameliorates necrotizing enterocolitis by preventing Th17/Treg imbalance through activation of the AMPK/SIRT1 pathway[J].Theranostics,2020,10(17):7730-7746.DOI:10.7150/thno.45862.
[15] Gao XY,Liu WK,Gao PM,et al.Melatonin-induced lncRNA LINC01512 prevents Treg/Th17 imbalance by promoting SIRT1 expression in necrotizing enterocolitis[J].Int Immunopharmacol,2021,96:107787.DOI:10.1016/j.intimp.2021.107787.
[16] Lai JH,Li F,Li HF,et al.Melatonin alleviates necrotizing enterocolitis by reducing bile acid levels through the SIRT1/FXR signalling axis[J].Int Immunopharmacol,2024,128:111360.DOI:10.1016/j.intimp.2023.111360.
[17] Kindon H,Pothoulakis C,Thim L,et al.Trefoil peptide protection of intestinal epithelial barrier function:cooperative interaction with mucin glycoprotein[J].Gastroenterology,1995,109(2):516-523.DOI:10.1016/0016-5085(95)90340-2.
[18] Liu JP,Yang Q,Chen ZY,et al.TFF3 mediates the NF-κB/COX2 pathway to regulate PMN-MDSCs activation and protect against necrotizing enterocolitis[J].Eur J Immunol,2021,51(5):1110-1125.DOI:10.1002/eji.202048768.
[19] Fawley J,Gourlay DM.Intestinal alkaline phosphatase:a summary of its role in clinical disease[J].J Surg Res,2016,202(1):225-234.DOI:10.1016/j.jss.2015.12.008.
[20] Singh SB,Carroll-Portillo A,Coffman C,et al.Intestinal alkaline phosphatase exerts Anti-Inflammatory effects against lipopolysaccharide by inducing autophagy[J].Sci Rep,2020,10(1):3107.DOI:10.1038/s41598-020-59474-6.
[21] Ardesia M,Ferlazzo G,Fries W.Vitamin D and inflammatory bowel disease[J].Biomed Res Int,2015,2015:470805.DOI:10.1155/2015/470805.
[22] Lyu CM,Jiang SH,Kong MX,et al.Vitamin D protects against necrotising enterocolitis in newborn mice by activating the ERK signalling pathway[J].Mol Med Rep,2020,22(3):2107-2114.DOI:10.3892/mmr.2020.11286.
[23] Cheng XQ,Zhang XF,Su JW,et al.miR-19b downregulates intestinal SOCS3 to reduce intestinal inflammation in Crohn’s disease[J].Sci Rep,2015,5:10397.DOI:10.1038/srep10397.
[24] Zhang H,Wang Y,Li SX,et al.SOCS3 protects against neonatal necrotizing enterocolitis via suppressing NLRP3 and AIM2 inflammasome activation and p65 nuclear translocation[J].Mol Immunol,2020,122:21-27.DOI:10.1016/j.molimm.2020.03.019.
相似文献/References:
[1]臧婧羽,袁小建,程思旸,等.单中心不同手术方式治疗全结肠型巨结肠疗效分析[J].临床小儿外科杂志,2018,17(02):106.
Zang Jingyu,Yuan Xiaojian,Cheng Siyang,et al.The efficacy analysis of different operative methods in treating Total Colonic Aganglionosis (TCA) in a Single Center.[J].Journal of Clinical Pediatric Surgery,2018,17(07):106.
[2]吴书清,钟斌,刘辉,等. Bishop-Koop 造瘘术和双口造瘘术在新生儿坏死性小肠结肠炎中的疗效比较[J].临床小儿外科杂志,2018,17(11):835.
Wu Shuqing,Zhong Bin,Liu Hui,et al. Comparison of therapeutic efficacies of BishopKoop stoma versus double mouth enterostomy for neonatal necrotizing enterocolitis.[J].Journal of Clinical Pediatric Surgery,2018,17(07):835.
[3]施诚仁.再谈先天性巨结肠小肠结肠炎的防治[J].临床小儿外科杂志,2019,18(05):348.[doi:10.3969/j.issn.1671-6353.2019.05.002]
Shi Chengren.Re-discussion on prevention and treatment of congenital megacolon enterocolitis[J].Journal of Clinical Pediatric Surgery,2019,18(07):348.[doi:10.3969/j.issn.1671-6353.2019.05.002]
[4]吕志宝,盛庆丰.新生儿坏死性小肠炎的病因与诊治研究进展[J].临床小儿外科杂志,2019,18(05):352.[doi:10.3969/j.issn.1671-6353.2019.05.003]
Lv Zhibao,Sheng Qingfeng.Advances in the etiology, diagnosis and treatment of neonatal necrotizing enterocolitis[J].Journal of Clinical Pediatric Surgery,2019,18(07):352.[doi:10.3969/j.issn.1671-6353.2019.05.003]
[5]安宗剑,孙勇.新生儿肠道菌群与坏死性小肠结肠炎发病关系的研究进展[J].临床小儿外科杂志,2019,18(05):356.[doi:10.3969/j.issn.1671-6353.2019.05.004]
An Zongjian,Sun Yong.Research advances of neonatal intestinal microbiome and necrotising enterocolitis[J].Journal of Clinical Pediatric Surgery,2019,18(07):356.[doi:10.3969/j.issn.1671-6353.2019.05.004]
[6]郑泽兵,刘远梅,张帆,等.降钙素原、白细胞介素6、C反应蛋白在新生儿坏死性小肠结肠炎手术时机选择中的应用价值研究[J].临床小儿外科杂志,2019,18(05):361.[doi:10.3969/j.issn.1671-6353.2019.05.005]
Zheng Zebing,Liu Yuanmei,Zhang Fan,et al.Applicable value of operative opportunity for procalcitonin, interleukin-6 and C-reactive protein in neonatal necrotizing enterocolitis[J].Journal of Clinical Pediatric Surgery,2019,18(07):361.[doi:10.3969/j.issn.1671-6353.2019.05.005]
[7]杜京斌,陈永卫,郭卫红,等.新生儿坏死性小肠结肠炎手术干预指征的回顾性研究[J].临床小儿外科杂志,2019,18(05):368.[doi:10.3969/j.issn.1671-6353.2019.05.006]
Du Jingbin,Chen Yongwei,Guo Weihong,et al.Retrospectivestudy of indications for surgical intervention inneonatal necrotizingenterocolitis[J].Journal of Clinical Pediatric Surgery,2019,18(07):368.[doi:10.3969/j.issn.1671-6353.2019.05.006]
[8]梁琼鹤,蒋维维,路长贵,等.新生儿肠道手术后并发坏死性小肠结肠炎的临床特征分析[J].临床小儿外科杂志,2019,18(05):372.[doi:10.3969/j.issn.1671-6353.2019.05.007]
Liang Qionghe,Jiang Weiwei,Lu Changgui,et al.Clinical characteristics of Necrotizing enterocolitis after neonatal intestinal surgery[J].Journal of Clinical Pediatric Surgery,2019,18(07):372.[doi:10.3969/j.issn.1671-6353.2019.05.007]
[9]陈发玲,徐伟珏,黄雄,等.一期肠切除肠吻合术治疗新生儿坏死性小肠结肠炎后肠狭窄[J].临床小儿外科杂志,2020,19(11):1016.[doi:10.3969/j.issn.1671-6353.2020.11.011]
Chen Faling,Xu Weijue,Huang Xiong,et al.Experience of treatment of intestinal stenosis after one-stage intestinal resectional anastomosis for neonatal necrotizing enterocolitis[J].Journal of Clinical Pediatric Surgery,2020,19(07):1016.[doi:10.3969/j.issn.1671-6353.2020.11.011]
[10]王大佳,张志波,白玉作.先天性巨结肠根治术后非计划再入院原因分析[J].临床小儿外科杂志,2021,20(03):217.[doi:10.12260/lcxewkzz.2021.03.004]
Wang Dajia,Zhang Zhibo,Bai Yuzuo.Unplanned readmissions of infants after pull-through for Hirschsprung disease[J].Journal of Clinical Pediatric Surgery,2021,20(07):217.[doi:10.12260/lcxewkzz.2021.03.004]
[11]侯龙龙 李仲荣 黄璜. 新生儿坏死性小肠结肠炎预后相关因素分析[J].临床小儿外科杂志,2014,13(05):396.
[12]史婧奕,吕志宝.. 双歧杆菌三联活菌散预防早产儿坏死性小肠结肠炎的临床初探[J].临床小儿外科杂志,2016,15(01):72.
[13]潘登,王献良,邵雷朋..新生儿坏死性小肠结肠炎经回肠造瘘术后远端肠闭锁7例[J].临床小儿外科杂志,2016,15(05):513.
[14]周思海,顾茜,刘晓莉,等.新生儿坏死性小肠结肠炎全麻手术后苏醒延迟的相关因素分析[J].临床小儿外科杂志,2021,20(10):968.[doi:10.12260/lcxewkzz.2021.10.014]
Zhou Sihai,Gu Qian,Liu Xiaoli,et al.Risk factors of delayed recovery after general anesthesia in infants with neonatal necrotizing enterocolitis[J].Journal of Clinical Pediatric Surgery,2021,20(07):968.[doi:10.12260/lcxewkzz.2021.10.014]
[15]高润楠,朱海涛,沈淳.坏死性小肠结肠炎体内外模型的研究进展[J].临床小儿外科杂志,2022,21(04):331.[doi:10.3760/cma.j.cn101785-202009024-007]
Gao Runnan,Zhu Haitao,Shen Chun.Research advances in models of necrotizing enterocolitis in vivo and in vitro[J].Journal of Clinical Pediatric Surgery,2022,21(07):331.[doi:10.3760/cma.j.cn101785-202009024-007]
[16]陈晓庆,朱利斌.近红外光谱技术在儿童肠道疾病诊治中的应用进展[J].临床小儿外科杂志,2022,21(10):991.[doi:10.3760/cma.j.cn101785-202111025-016]
Chen Xiaoqing,Zhu Libin.Recent advances of clinical application of near infrared spectroscopy technology for pediatric intestinal diseases[J].Journal of Clinical Pediatric Surgery,2022,21(07):991.[doi:10.3760/cma.j.cn101785-202111025-016]
[17]徐铃琪,马淑蓉,陈璐璐,等.坏死性小肠结肠炎动物模型建立方法的改进与评价[J].临床小儿外科杂志,2023,22(06):569.[doi:10.3760/cma.j.cn101785-202202036-014]
Xu Lingqi,Ma Shurong,Chen Lulu,et al.Improvements and evaluations of animal models of neonatal necrotizing enterocolitis[J].Journal of Clinical Pediatric Surgery,2023,22(07):569.[doi:10.3760/cma.j.cn101785-202202036-014]
[18]朱乐道,陈杨,周令,等.外泌体治疗新生儿坏死性小肠结肠炎的研究进展[J].临床小儿外科杂志,2024,23(12):1197.[doi:10.3760/cma.j.cn101785-202211007-017]
Zhu Ledao,Chen Yang,Zhou Ling,et al.Research advances of exosomes in the treatment of neonatal necrotizing enterocolitis[J].Journal of Clinical Pediatric Surgery,2024,23(07):1197.[doi:10.3760/cma.j.cn101785-202211007-017]
备注/Memo
收稿日期:2024-5-25。
基金项目:首都医科大学“本科生科研创新”项目(XSKY2023333)
通讯作者:李樱子,Email:Liang05124300@163.com